Suchergebnisse - "Eriksson, Niclas"

PubPharm (16)

1

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation

enthalten in: European heart journal | 2020

von Wallentin, L. | Lindbäck, J. | Eriksson, N. | +8

CommentIn: Eur Heart J. 2020 Nov 1;41(41):4047-4049. - PMID 33118012

2

Novel regulatory variant detected on the VKORC1 haplotype that is associated with warfarin dose

enthalten in: Pharmacogenomics | 2016

von Cavalli, M. | Pan, G. | Nord, H. | +3

3

Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range : a RE-LY genomics substudy

enthalten in: Pharmacogenomics | 2016

von Eriksson, N. | Wallentin, L. | Berglund, L. | +12

4

A randomized trial of genotype-guided dosing of warfarin

enthalten in: The New England journal of medicine | 2013

von Pirmohamed, M. | Burnside, G. | Eriksson, N. | +29

CommentIn: N Engl J Med. 2013 Dec 12;369(24):2345-6. - PMID 24251364

5

Estimated glomerular filtration rate is associated with major bleeding complications but not thromboembolic events, in anticoagulated patients taking warfarin

enthalten in: Thrombosis research | 2013

von Wieloch, M. | Jönsson, K. | Själander, A. | +3

CommentIn: Thromb Res. 2013 Jun;131(6):469-71. - PMID 23518011

6

Prediction of warfarin dose : why, when and how?

enthalten in: Pharmacogenomics | 2012

von Eriksson, N. | Wadelius, M.

7

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy

enthalten in: Thrombosis and haemostasis | 2012

von Horne, B. | Lenzini, P. | Wadelius, M. | +26

8

Anticoagulation control in Sweden : reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA

enthalten in: European heart journal | 2011

von Wieloch, M. | Själander, A. | Frykman, V. | +3

9

Warfarin pharmacogenetics : a single VKORC1 polymorphism is predictive of dose across 3 racial groups

enthalten in: Blood | 2010

von Limdi, N. | Wadelius, M. | Cavallari, L. | +87

10

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

enthalten in: PLoS genetics | 2009

von Takeuchi, F. | McGinnis, R. | Bourgeois, S. | +12